Varian IMRT Technology Makes Investors Beam; Stock Up 18% In Q2
This article was originally published in The Gray Sheet
Executive Summary
The growing demand for advanced radiation therapy systems in the U.S. combined with a predictable revenue stream made Varian Medical Systems an investor favorite in the second quarter. The firm's stock price rose 10.70 points (17.6%) during the three months ended June 29 to $71.50.
You may also be interested in...
Guidant Solution To Panel Dilemma Will Not Require New Contak Implants
Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.